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Chronic hepatitis C is associated with pro-
gressive liver disease in a considerable proportion
of patients. 10–20% of patients with chronic hep-
atitis C will develop cirrhosis within 20 years and
are at risk for complications. Annually ~5% will
decompensate and ~2–4% will develop hepatocel-
lular carcinoma, leading to a 5-year mortality rate
of ~20% [1–3]. Concomitant daily alcohol con-
sumption (>25–50 g/d), older age at infection (>40
years), co-infection with HBV or HIV, and male
gender are known to speed up progression to cir-
rhosis [4–8].
Background/aim: Roughly 50% of patients with
chronic hepatitis C, who relapsed after a previous
monotherapy with interferon alpha, will respond
in a sustained fashion to 24 weeks of re-therapy
with the combination of interferon alpha plus riba-
virin. Whether prolonging treatment duration to
48 weeks will further increase sustained response
rates remains ill defined. In this randomised con-
trolled pilot trial we compared the efficacy and tol-
erability of a 24 week with that of a 48 week course
of combination therapy with interferon alpha and
ribavirin in interferon monotherapy relapsers with
chronic hepatitis C.
Methods: Interferon alpha monotherapy re-
lapsers with chronic hepatitis C were randomised
to receive interferon alpha 2b (3  3 MIU sc
weekly) and oral ribavirin (1000/1200 mg po daily)
for either 24 weeks or 48 weeks. Virological re-
sponse was evaluated by HCV RNA PCR at week
10 (initial response), at the end of treatment (end-
of-treatment response) and at the end of 24 weeks
follow-up (sustained response). Only patients with
negative HCV RNA at week 10 continued treat-
ment. Adverse events were recorded at regular
intervals.
Results: Thirty-seven patients were enrolled,
19 (6 females, median age 43) in the 24 week and
18 (5 females, median age 40) in the 48 week treat-
ment arm. Baseline characteristics were similar in
both groups. At treatment week 10, 12/19 (63%)
in the 24 week group and 14/18 (78%) patients in
the 48 week group had lost HCV RNA in serum
(p = 0.33). All initial responders remained HCV
RNA negative throughout the treatment period.
Sustained response rates were 10/19 (53%) in the
24 week group and 13/18 (72%) in the 48 week
group (p = 0.31). Three patients discontinued
treatment early (two due to moderate adverse
events, one due to non-compliance). Dose modi-
fications were necessary in 9 patients, 4 in the 24
week and 5 in the 48 week group for anaemia, neu-
tropenia, nausea and depression, respectively.
Conclusion: Prolonging interferon / ribavirin
combination therapy in interferon alpha mono-
therapy relapsers with chronic hepatitis C from 
24 to 48 weeks may increase sustained response
rates. Larger controlled trials using pegylated 
interferon alpha and ribavirin in relapsers with
chronic hepatitis C seem warranted.
Key words: hepatitis C; relapse; combination ther-
apy; interferon alpha; ribavirin; SASL
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Introduction
Monotherapy with interferon alpha was the
first treatment of proven efficacy for chronic hep-
atitis C. About 20% of patients achieved a sus-
tained response rate, i.e. long-term HCV clear-
ance [9–11]. Monotherapy with ribavirin – a syn-
thetic nucleoside analogue – led to a reduction of
alanine aminotransferase, but not to clearance of
serum HCV RNA [12–15]. More recently, large
controlled trials demonstrated that combining in-
terferon alpha and ribavirin increases antiviral ef-
ficacy, i.e. sustained response rates to 36–46% in
previously untreated patients [6, 7, 16–18]. A 24
week course of re-treatment of relapsers to inter-
feron alpha monotherapy with interferon alpha
and ribavirin leads to sustained HCV clearance in
approximately 50% of patients [19]. Whether this
encouraging response rate can be further im-
proved by prolonging treatment to 48 weeks is
unknown.
The aim of this pilot study was, therefore, to
compare the efficacy and tolerability of 24 versus
48 weeks of combination therapy with interferon
alpha and ribavirin in interferon alpha monother-
apy relapsers with chronic hepatitis C.
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Methods
Patients
Eligible for the study were adult patients, aged be-
tween 18 and 65 years, with biopsy proven chronic hepa-
titis C who had relapsed, i.e. were HCV RNA negative in
serum at the end of a previous treatment with interferon
alpha alone (≥3  3 MIU sc weekly for ≥24 weeks), but
became HCV RNA positive again within 24 weeks of fol-
low-up after cessation of treatment. Biopsies must have
been performed within the last 5 years and METAVIR [20,
21] scored for degree of inflammation and fibrosis. HCV
genotype was determined by the GeneBank database when
not provided by local investigators.
In addition, the following criteria had to be fulfilled:
(1) Elevation of alanine aminotransferase (ALT) above
normal value on three occasions within 24 weeks; (2) de-
tection of HVC RNA by PCR in serum (Cobas Amplicor®
HCV Monitor™ v2.0, Roche Diagnostics, Switzerland);
(3) the following minimal haematological, biochemical
and serological criteria: Haemoglobin concentration >12
g/100 ml in women and >13 g/100 ml in men; white-cell
count of >3.0 G/l, neutrophil count of >1.5 G/l; platelet
count of >100 G/l, bilirubin, prothrombin time, serum
albumin, uric acid, serum creatinin, fasting blood glucose,
TSH, alpha-1-antitrypsin, caeruloplasmin and alpha-fe-
toprotein within normal range, ferritin less than 1000 mg/l,
antinuclear antibodies (ANA) <1:160, anti-smooth-mus-
cle antibodies and anti-mitochondrial antibodies negative.
Additional exclusion criteria were: HbsAg positivity, HIV
infection, alcohol consumption ≥50 g weekly; illicit drug
use within the last 12 months, severe cardiovascular
disease, severe psychiatric conditions, a seizure disorder,
prior organ transplantation, immunosuppression, and
pregnancy or lactation. All women in the study were
required to practice adequate contraception.
Study design and treatment regimens
This is a prospective, randomised, controlled, multi-
centre, parallel group pilot trial conducted on behalf of the
Swiss Association for the Study of the Liver (SASL). Re-
cruitment in 15 Swiss centres started in February 1999 and
continued until February 2000. Patients were randomised
in blocks of 10 to receive interferon alpha-2b 3 MIU sc
TIW and ribavirin (b.w. <75 kg: 1000 mg po daily; b.w.
≥75 kg: 1200 mg po daily; in two divided doses) either for
24 or 48 weeks, respectively. The study was conducted in
accordance with the Declaration of Helsinki and approved
by the local ethics committee of all participating centres
and the Swiss federal regulatory authorities (Interkan-
tonale Kontrollstelle für Heilmittel/SwissMedic). During
treatment patients were followed twice monthly until
week 10 and monthly thereafter. At each visit, blood sam-
ples were gathered and concomitant medication and
adverse events recorded according to the protocol.
Biochemical (ALT) and virological (HCV RNA)
response was assessed at the end of treatment week 10 
(if HCV RNA remained positive, treatment was stopped),
at the end of treatment week 24 or 48 respectively (end-
of-treatment response) and 24 weeks after cessation of
treatment, where sustained response was determined.
End points
Primary end point was a sustained biochemical and
virological response, i.e. normal ALT and undetectable
HCV RNA in serum 24 weeks after completion of the
treatment course.
Secondary end points were initial (at the end of
treatment week 10) and end-of-treatment virological re-
sponses (HCV RNA in serum undetectable). In addition,
tolerability (adverse events) was recorded and factors po-
tentially associated with virological response explored.
Statistical analysis
Data were analysed with an intention to treat per-
spective, i.e. including all patients who received at least
one dose of study drug. Data collection was fairly com-
plete. Missing variables were not imputed. The final
model contained no missing variables. If normality of nu-
meric data was not rejected by the Wilk-Shapiro test, base-
line-variables were compared by t-tests. If normality was
questionable, a Wilcoxon rank-sum test was performed.
Categorical variables were analysed by Fisher’s exact test
or the Mantel-Haenszel Chi-Square test for trend, as
appropriate. No correction for multiple testing was used
because the main outcome was not statistically significant.
Finally the variables treatment group, viral genotype (1 vs.
other than 1), gender, age, viral load, degree of histologi-
cal inflammation, and fibrosis were included in a stepwise
logistic regression model. These variables were selected
according to previous descriptions in the literature.
Statistical analysis was performed using the statistical
package SAS version 8 e (SAS Institute, Cary, North Car-
olina, USA).
Characteristics of patients
Baseline characteristics are detailed in table 1.
Demographics, mode of HCV transmission, geno-
type distribution and viraemia, histological grad-
ing and staging, and previous interferon alpha
therapy (dose, duration) were similar in both
groups.
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Results
Characteristics 24 week treatment group 48 week treatment group
no. and sex (m/f) of patients 19 (13/6) 18 (13/5)
median age (range) 43.0 (32–60) 39.5 (30–65)
median weight in kg (range) 74.0 (56–104) 78.0 (60–121)
median BMI (range) 23.2 (19.1–32.1) 26.2 (21.3–41.9)
source of infection
parenteral 14 9
sporadic 5 9
histology
inflammation
none / mild 11 12
moderate / severe 8 5
fibrosis
none / mild 9 8
moderate / severe / cirrhosis 9 9
ALT level 150.8 ± 80.8 167.3 ± 91.0
HCV genotype
1 4 5
non-1 15 13
serum HCV RNA
>2  106 copies/ml 5 7
<2  106 copies/ml 14 11
previous IFN treatment
median duration (weeks) 45.2 45.6
median total IFN dose (MU) 524.5 448.3
Table 1
Comparison of base-
line characteristics.
18
13
14
week 10
initial
response
week 24 / 48
end of
treatment
follow-up
inclusion
end of
follow-up
sustained
response
48 week
treatment group
study
phase
19
10
12
24 week
treatment group
6 non-responders
1 drop-out
2 relapsers
2 non-responders
2 drop-outs
1 relapser
Figure 1
Flow chart of the 
results of 37 included
patients in the 24
week and 48 week
treatment groups.
Virological and biochemical response
The detailed treatment course is shown in fig-
ure 1. The treatment phase was successfully com-
pleted by all patients who had responded at week
10: 12 in the 24 week group (63%) and 14 in the
48 week group (78%). At the end of follow-up, two
patients in the 24 week and one patient in the 48
week treatment regimen had suffered a relapse.
After adjustment for viral genotype, the odds ratio
for sustained virological response at the end of fol-
low-up was 3.1 (95% CI 0.7–14.4, p = 0.14). 
The response rates at crucial points are dis-
played in figure 2.
Factors associated with a response
Significantly higher response rates could only
be observed in carriers of a genotype other than 1
compared to those with genotype 1 irrespective of
the groups at all time points with an odds ratio 
of 6.3 (95% CI 1.1–35.6, p = 0.037) for sustained
virological and biochemical response at the end of
follow-up.
Differences in histological inflammation, fi-
brosis score, serum HCV RNA and ferritin levels
did not predict sustained virological response. The
subgroups were too small to allow for statistical
testing (table 2).
Tolerability
Subjectively perceived adverse events, well
known for ribavirin and interferon alpha, were
recorded in 1 patient in the 24 week and 2 patients
in the 48 week treatment arm, respectively.
The mean decrease of haemoglobin concen-
tration under therapy was slightly less pronounced
in the 24 week treatment regimen with values
below 110 g/l in 26% versus 39% in the 48 week
group (ns).
Fatigue and headache in one patient in the 24
week group and severe dizziness and persistent
concentration and sleep disturbance in one patient
in the 48 week group led to premature discontin-
uation of treatment. The second dropout in the
latter group was due to non-compliance.
Dose modifications, both temporary interrup-
tion and reduction, were necessary in five patients
in the 24 week arm (26.3%) and four patients in
the 48 week arm (22.2%) (ns). Reasons included
anaemia, neutropenia, nausea and vomiting, de-
pressive symptoms, allergic exanthema, severe
pruritus, and severe fatigue.
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Figure 2
Response rates in
percent at week 10,
at end of treatment,
and at end of follow-
up (sustained 
response).
Characteristics* 24 week treatment group 48 week treatment group
SR/* % SR/* %
all 10/19 53 13/18 72
sex male 8/13 62 9/13 69
female 2/6 33 4/5 80
genotype
1 1/4 25 2/5 40
other than 1 9/15 60 11/13 85
histology
inflammation
none/mild 4/11 36 10/12 83
moderate/severe 6/8 75 2/5 40
fibrosis
none/mild 3/9 33 8/8 100
moderate/severe/cirrhosis 7/10 70 4/9 44
serum level HCV RNA
<2 106 copies/ml 7/14 50 9/11 82
>2 106 copies/ml 3/5 60 4/7 57
Table 2
Rates of sustained 
response (SR) to
treatment according
to baseline character-
istics (statistics were
not performed due 
to small numbers).
The presented comparison of 24 week versus
48 week combination treatment in chronic hepa-
titis C with interferon alpha 2b and ribavirin in
previous interferon-monotherapy relapsers was
designed on the basis of the observation, that com-
bination therapy of interferon alpha and ribavirin
on one hand [19] and prolonging interferon
monotherapy on the other hand [22, 23] were
proven to be more effective than interferon alone
in both naive [6, 10, 24] and relapse [22, 25–27]
patients.
The primary aim of any treatment regimen in
chronic hepatitis C – efficacy is generally assessed
by clearance of HCV RNA, ALT normalisation,
and histological improvement – is the prevention
of progression and its fatal complications cirrhosis
and hepatocellular carcinoma.
In our study, the overall sustained response
rate of 62% 24 weeks after end of treatment
demonstrates the high effectiveness of this well-
tolerated combination therapy and is in line with
previous study results of 49% and 54% [19, 28].
Prolonging the therapy from 24 to 48 weeks
resulted in a higher sustained response rate of 72%
versus 53% without higher rates of adverse events.
Similar data were recently published [28] with a
72% versus 36% response rate (p = 0.01).
Infections with a genotype other than geno-
type 1 responded better, confirming other studies
[6, 7, 28].
Due to small numbers we could not demon-
strate a statistical significance in our primary end-
point results, nor could the role of variables such
as age, sex, and histological or biochemical find-
ings be clarified. Reasons for the limited scope are
the highly focused patient group, strict inclusion
and exclusion criteria and the complex protocol
with a 10 week stopping rule on failed HCV clear-
ance. No further patients were included after
promising data on pegylated interferon and its
combination with ribavirin emerged during the
course of the study. Nevertheless our results
demonstrate the high sustained response rates of
this combination therapy, particularly in the pro-
longed treatment regimen. Therefore this pilot
trial encourages further studies, exploring the
effectiveness of a 48 week treatment with PEG
interferon combined with ribavirin in both inter-
feron alpha mono- and combination therapy
relapsers.
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